raloxifene has been researched along with Leiomyoma in 1 studies
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.
Leiomyoma: A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hummel, CW | 1 |
| Geiser, AG | 1 |
| Bryant, HU | 1 |
| Cohen, IR | 1 |
| Dally, RD | 1 |
| Fong, KC | 1 |
| Frank, SA | 1 |
| Hinklin, R | 1 |
| Jones, SA | 1 |
| Lewis, G | 1 |
| McCann, DJ | 1 |
| Rudmann, DG | 1 |
| Shepherd, TA | 1 |
| Tian, H | 1 |
| Wallace, OB | 1 |
| Wang, M | 1 |
| Wang, Y | 1 |
| Dodge, JA | 1 |
1 other study available for raloxifene and Leiomyoma
| Article | Year |
|---|---|
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
Topics: Animals; Binding Sites; Biological Availability; Cell Line; Cell Proliferation; Estradiol; Estrogen | 2005 |